[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US7855181B2 - Dipeptides for prevention of muscle breakdown and microbial infection - Google Patents

Dipeptides for prevention of muscle breakdown and microbial infection Download PDF

Info

Publication number
US7855181B2
US7855181B2 US10/704,936 US70493603A US7855181B2 US 7855181 B2 US7855181 B2 US 7855181B2 US 70493603 A US70493603 A US 70493603A US 7855181 B2 US7855181 B2 US 7855181B2
Authority
US
United States
Prior art keywords
dipeptide
dipeptides
glutamine
subject invention
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/704,936
Other versions
US20040097426A1 (en
Inventor
Josef Neu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Priority to US10/704,936 priority Critical patent/US7855181B2/en
Publication of US20040097426A1 publication Critical patent/US20040097426A1/en
Priority to US12/253,590 priority patent/US8133868B2/en
Assigned to UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. reassignment UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF FLORIDA
Application granted granted Critical
Publication of US7855181B2 publication Critical patent/US7855181B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • proteins are converted to amino acids in the digestive system and that the resulting amino acids are used by the body for growth and development.
  • a patient may be unable to receive proteins.
  • patients have been given free amino acids. Free amino acids, however, are sometimes not tolerated well by patients and may cause diarrhea and dehydration. Also, the free amino acids may be unstable and/or difficult to formulate.
  • dipeptides or tripepetides consist of, for example, two to three amino acids. It has been observed, for example, that peptides containing the amino acid residue glycine in the N-terminal position are readily assimilable. See for example, U.S. Pat. No. 4,340,592.
  • European Patent Application No. 0,182,356 discloses a nutritional composition containing at least one oligopeptide consisting of a dipeptide or a tripeptide wherein the N-terminal amino acid residue is selected from the class consisting of alanine, lysine and arginine.
  • glycine is generally superior to other amino acids as the N-terminal amino acid residue in a dipeptide. This superiority was attributed to a greater fraction of such an intravenously administered dipeptide reaches the tissues.
  • S. Adibi et al. Influence of Molecular Structure on Half - life and Hydrolysis of Dipeptides in Plasma: Importance of Glycine as N - Terminal Amino Acid Residue , 35 Metabolism 850, 835 (1986).
  • the '751 patent discloses a method to parenterally administer low water-soluble amino acids. Two amino acids, tyrosine and cystine, individually have low solubility in water. These amino acids, however, are clinically useful and, therefore, it was desirable to, find an effective formulation.
  • the '751 patent describes an infusion method which involves bonding these relatively insoluble amino acids to the amino acid lysine to produce a tripeptide.
  • the '750 patent discloses the infusion of glutamine as a derivative substituted by ⁇ -aminoacyl residues on the ⁇ amino group. That is, glutamine is in the “c-terminal” position, in that its alpha amino nitrogen becomes part of the peptide bond with the other amino acid.
  • the preferred dipeptide preparation disclosed in the '750 patent is alanyl-glutamine. The aminoacylation of glutamine is reported to achieve a stabilization of the terminal amide group.
  • TPN total parenteral nutrition
  • Mucosal immunity provides a first line of defense for the body against a broad range of pathogens.
  • compositions and methods which promote healthy muscle tissue, reduce muscle deterioration, and/or promote a healthy immune system.
  • the subject invention provides materials and methods useful in promoting healthy muscle tissue.
  • the promotion of healthy muscle tissue according to the subject invention is particularly advantageous for athletes and others engaging in rigorous physical exertion and/or training.
  • the promotion of healthy muscle tissue according to the subject invention is also advantageous for the treatment and/or prevention of muscle wasting conditions. This is particularly advantageous for critically ill hospitalized patients including neonates.
  • compositions of the subject invention are also useful in promoting mucosal immunity.
  • Such immunity which is often typified by an IgA response, can be a critical defense against a variety of human and animal pathogens.
  • pathogens may be, for example, bacteria, viruses, or parasites.
  • the amino acids arginine and glutamine are combined as the dipeptide arginyl-glutamine in order to provide beneficial effects in a safe, easily absorbable formulation.
  • the dipeptide of the subject invention promotes healthy muscle tissue and an advantageous immune response.
  • the dipeptide of the subject invention is also advantageous because it is safe for human or animal consumption and can be readily formulated in an aqueous solution for internal consumption.
  • compositions of the subject invention can be used in a variety of situations where it is desired to promote healthy muscle tissue.
  • the dipeptides of the subject invention can be used in medical applications to aid critically ill patients.
  • the arginyl-glutamine dipeptide can be applied to enhance athletic performance.
  • compositions can also be used to promote a healthy immune system in humans or animals. This is particularly advantageous for patients and hospital workers, or others who may be exposed to pathogens.
  • peptides of the subject invention can be administered as one component of a nutrient composition.
  • the use of these peptides compared to the administration of equivalent amounts of the free amino acids, cause a decrease in osmolarity of the solution, facilitate the administration of amino acids having low water solubility, and stabilize heat unstable amino acids such as glutamine.
  • the aqueous solution is suitable for intravenous feeding or for intragastrointestional administration.
  • the aqueous solution itself may contain other nutrient additives such as fats, glucose, mono- or oligo-saccharides, minerals, trace elements and/or vitamins.
  • the present invention relates to nutrient compositions containing dipeptides and methods for administering the same.
  • the subject invention provides a dipeptide having water solubility, stability to sterilization, long-term stability, and bioavailability for humans and animals.
  • a preferred embodiment of the present invention provides a nutrient composition comprising an aqueous solution having at least one arginyl-glutamine dipeptide.
  • the arginine moiety is particularly advantageous because it is a creatine phosphate precursor, a stimulator of immune function, a stimulator of growth hormone production and, in combination with glutamine, is particularly useful in strengthening mucosal immune defenses.
  • the arginyl-glutamine dipeptides described herein are useful for promoting healthy muscle tissue.
  • these dipeptides can be used by athletes or others who are undergoing training or other rigorous physical exertion.
  • the dipeptide compositions of the subject invention can also be used to promote muscle repair and maintenance in hospital or hospice patients, or other individuals subject to muscle deterioration.
  • the subject invention provides materials and methods for enhancing the immune system functioning of humans and animals.
  • compositions which comprise the arginyl-glutamine dipeptide are administered to people or animals who could benefit from an improved immune response.
  • the dipeptides of the subject invention can be used to enhance mucosal immunity. This enhancement of mucosal immunity reduces the risk of infection by a variety of pathogens including bacteria, viruses, and parasites.
  • compositions of the subject invention are particularly attractive for use in hospitals.
  • compositions containing the dipeptide of the subject invention can be used to maintain muscle mass in inactive patients while having the added benefit of reducing susceptibility to hospital acquired infections in patients.
  • aqueous clinical nutrient compositions can be prepared which include at least one arginyl-glutamine dipeptide.
  • the dipeptide can be added to enteral or parenteral formulations of either complete or incomplete nutritional content.
  • Each dipeptide has an N-terminal amino acid which is arginine.
  • the C-terminal amino acid is glutamine.
  • the concentration of the dipeptide in the aqueous solution can be, for example, from about 0.1 to about 25.0 percent by weight.
  • the clinical nutritional solution can contain, for example, dextrose, liquid emulsions, vitamins, minerals and trace elements. The selection of the particular dipeptide formulation depends upon the particular use.
  • Dipeptide additives such as single or multiple entities, as well as a total nutritional formulation which contains dipeptides as one component among many are contemplated by this invention.
  • the aqueous dipeptide formulation may be ingested orally along with other nutrients such as conventional foods or prepared vitamins, fats, glucose or other mono-saccharides, oligosaccharides, minerals and trace elements.
  • a supply of the dipeptide solution may be merged through a Y-connection with a supply of glucose solution or other parenteral solutions.
  • the dipeptide solutions may be mixed with glucose solutions and/or other parenteral solutions to create a mixture which may be administered parenterally.
  • dipeptides rather than free amino acids allows administration of the same amount of amino acid residue in solutions which are less hypertonic and therefore can be introduced into peripheral veins.
  • dipeptides of the subject invention can be readily synthesized and/or formulated by a person skilled in the art having the benefit of the instant disclosure.
  • the dipeptides can be purchased commercially from, for example, Bachem Biosciences, Inc. which sells the H—Arg—Glu—OH salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention provides dipeptides useful in promoting healthy muscle tissues as well as effective immune responses. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation of application Ser. No. 09/636,491, filed Aug. 11, 2000 now abandoned; which claims the benefit of U.S. Provisional Application No. 60/149,369, filed Aug. 13, 1999.
BACKGROUND OF THE INVENTION
Prevention or inhibition of muscle breakdown, and the facilitation of efficient muscle repair is of great interest to athletes, the elderly, and those with muscle-wasting conditions. A wide range of products and methods have been proposed for enhancing healthy muscle tissues and enhancing athletic performance. Existing compositions and methods which are available for these purposes suffer from a variety of shortcomings. These shortcomings range from potentially dangerous side affects, to a lack of bioavailability and difficulty in formulation and/or administration.
It is well known that proteins are converted to amino acids in the digestive system and that the resulting amino acids are used by the body for growth and development. In certain medical situations a patient may be unable to receive proteins. In these situations patients have been given free amino acids. Free amino acids, however, are sometimes not tolerated well by patients and may cause diarrhea and dehydration. Also, the free amino acids may be unstable and/or difficult to formulate.
It has been observed that the body can more effectively absorb certain small molecules called dipeptides or tripepetides. These molecules consist of, for example, two to three amino acids. It has been observed, for example, that peptides containing the amino acid residue glycine in the N-terminal position are readily assimilable. See for example, U.S. Pat. No. 4,340,592.
European Patent Application No. 0,182,356 discloses a nutritional composition containing at least one oligopeptide consisting of a dipeptide or a tripeptide wherein the N-terminal amino acid residue is selected from the class consisting of alanine, lysine and arginine.
One group conducting research in this area concluded that glycine is generally superior to other amino acids as the N-terminal amino acid residue in a dipeptide. This superiority was attributed to a greater fraction of such an intravenously administered dipeptide reaches the tissues. S. Adibi et al., Influence of Molecular Structure on Half-life and Hydrolysis of Dipeptides in Plasma: Importance of Glycine as N-Terminal Amino Acid Residue, 35 Metabolism 850, 835 (1986).
Two European patents, 0,087,751 and 0,087,750 disclose water-soluble peptides. The '751 patent discloses a method to parenterally administer low water-soluble amino acids. Two amino acids, tyrosine and cystine, individually have low solubility in water. These amino acids, however, are clinically useful and, therefore, it was desirable to, find an effective formulation. The '751 patent describes an infusion method which involves bonding these relatively insoluble amino acids to the amino acid lysine to produce a tripeptide.
The '750 patent discloses the infusion of glutamine as a derivative substituted by α-aminoacyl residues on the α amino group. That is, glutamine is in the “c-terminal” position, in that its alpha amino nitrogen becomes part of the peptide bond with the other amino acid. The preferred dipeptide preparation disclosed in the '750 patent is alanyl-glutamine. The aminoacylation of glutamine is reported to achieve a stabilization of the terminal amide group.
Experiments involving the use of total parenteral nutrition (TPN) containing glycyl-glutamine dipeptides, however, suggest potential adverse effects of the TPN formulation containing glycyl-glutamine (U.S. Pat. No. 5,189,016).
Two commercially available dipeptides of glutamine are Dipeptiven, which is an alanyl-glutamine (Fresenius Laboratories, Germany) and Glamin (Pharmacia and Upjohn Laboratory, Sweden), which is an amino acid solution containing glycyl-glutamine dipeptide. To this date, there are no studies of the arginyl-L-glutamine dipeptide.
It is well known that nutrition can impact the functioning of the immune system. Proper nutrition can promote healthy immune responses. There are many aspects to the immune response of humans and animals. One component of the immune response is mucosal immunity. Mucosal immunity provides a first line of defense for the body against a broad range of pathogens.
There remains a great need in the art for compositions and methods which promote healthy muscle tissue, reduce muscle deterioration, and/or promote a healthy immune system.
BRIEF SUMMARY OF THE INVENTION
In one embodiment, the subject invention provides materials and methods useful in promoting healthy muscle tissue. The promotion of healthy muscle tissue according to the subject invention is particularly advantageous for athletes and others engaging in rigorous physical exertion and/or training. The promotion of healthy muscle tissue according to the subject invention is also advantageous for the treatment and/or prevention of muscle wasting conditions. This is particularly advantageous for critically ill hospitalized patients including neonates.
The compositions of the subject invention are also useful in promoting mucosal immunity. Such immunity, which is often typified by an IgA response, can be a critical defense against a variety of human and animal pathogens. These pathogens may be, for example, bacteria, viruses, or parasites.
In a preferred embodiment of the subject invention, the amino acids arginine and glutamine are combined as the dipeptide arginyl-glutamine in order to provide beneficial effects in a safe, easily absorbable formulation. The dipeptide of the subject invention promotes healthy muscle tissue and an advantageous immune response. The dipeptide of the subject invention is also advantageous because it is safe for human or animal consumption and can be readily formulated in an aqueous solution for internal consumption.
The compositions of the subject invention can be used in a variety of situations where it is desired to promote healthy muscle tissue. For example, the dipeptides of the subject invention can be used in medical applications to aid critically ill patients. Also, the arginyl-glutamine dipeptide can be applied to enhance athletic performance.
The compositions can also be used to promote a healthy immune system in humans or animals. This is particularly advantageous for patients and hospital workers, or others who may be exposed to pathogens.
These peptides of the subject invention can be administered as one component of a nutrient composition. The use of these peptides, compared to the administration of equivalent amounts of the free amino acids, cause a decrease in osmolarity of the solution, facilitate the administration of amino acids having low water solubility, and stabilize heat unstable amino acids such as glutamine. The aqueous solution is suitable for intravenous feeding or for intragastrointestional administration. The aqueous solution itself may contain other nutrient additives such as fats, glucose, mono- or oligo-saccharides, minerals, trace elements and/or vitamins.
DETAILED DISCLOSURE OF THE INVENTION
The present invention relates to nutrient compositions containing dipeptides and methods for administering the same. Advantageously, the subject invention provides a dipeptide having water solubility, stability to sterilization, long-term stability, and bioavailability for humans and animals. A preferred embodiment of the present invention provides a nutrient composition comprising an aqueous solution having at least one arginyl-glutamine dipeptide.
Among the advantages of the dipeptide of the subject invention over the existing alanyl-glutamine and glycyl-glutamine-dipeptides is that the arginine moiety is particularly advantageous because it is a creatine phosphate precursor, a stimulator of immune function, a stimulator of growth hormone production and, in combination with glutamine, is particularly useful in strengthening mucosal immune defenses.
In one embodiment of the subject invention the arginyl-glutamine dipeptides described herein are useful for promoting healthy muscle tissue. Thus, these dipeptides can be used by athletes or others who are undergoing training or other rigorous physical exertion. The dipeptide compositions of the subject invention can also be used to promote muscle repair and maintenance in hospital or hospice patients, or other individuals subject to muscle deterioration.
In a further embodiment, the subject invention provides materials and methods for enhancing the immune system functioning of humans and animals. In this embodiment, compositions which comprise the arginyl-glutamine dipeptide are administered to people or animals who could benefit from an improved immune response. Specifically, the dipeptides of the subject invention can be used to enhance mucosal immunity. This enhancement of mucosal immunity reduces the risk of infection by a variety of pathogens including bacteria, viruses, and parasites.
In view of the muscle maintenance characteristics of the arginyl-glutamine dipeptide combined with its ability to stimulate an effective immune response, the compositions of the subject invention are particularly attractive for use in hospitals. For example, compositions containing the dipeptide of the subject invention can be used to maintain muscle mass in inactive patients while having the added benefit of reducing susceptibility to hospital acquired infections in patients.
In accordance with the teachings provided herein, aqueous clinical nutrient compositions can be prepared which include at least one arginyl-glutamine dipeptide. The dipeptide can be added to enteral or parenteral formulations of either complete or incomplete nutritional content. Each dipeptide has an N-terminal amino acid which is arginine. The C-terminal amino acid is glutamine.
The concentration of the dipeptide in the aqueous solution can be, for example, from about 0.1 to about 25.0 percent by weight. In addition to dipeptides, the clinical nutritional solution can contain, for example, dextrose, liquid emulsions, vitamins, minerals and trace elements. The selection of the particular dipeptide formulation depends upon the particular use.
Dipeptide additives such as single or multiple entities, as well as a total nutritional formulation which contains dipeptides as one component among many are contemplated by this invention.
The aqueous dipeptide formulation may be ingested orally along with other nutrients such as conventional foods or prepared vitamins, fats, glucose or other mono-saccharides, oligosaccharides, minerals and trace elements. For parenteral administration, a supply of the dipeptide solution may be merged through a Y-connection with a supply of glucose solution or other parenteral solutions. The dipeptide solutions may be mixed with glucose solutions and/or other parenteral solutions to create a mixture which may be administered parenterally.
The administration of dipeptides rather than free amino acids allows administration of the same amount of amino acid residue in solutions which are less hypertonic and therefore can be introduced into peripheral veins.
The dipeptides of the subject invention can be readily synthesized and/or formulated by a person skilled in the art having the benefit of the instant disclosure. Alternatively, the dipeptides can be purchased commercially from, for example, Bachem Biosciences, Inc. which sells the H—Arg—Glu—OH salt.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims (2)

1. A total nutritional formulation for enteral administration to a human wherein said formulation comprises, in addition to vitamins, minerals, trace elements, fats, monosaccharides and/or oligosaccharides, an arginyl-glutamine dipeptide wherein the arginine residue is the amino terminus of said dipeptide and the glutamine residue is the carboxy terminus of said dipeptide and wherein the dipeptide is present in said formulation at a concentration of about 0.1% to about 25% by weight.
2. The formulation, according to claim 1, which has no free amino acids.
US10/704,936 1999-08-13 2003-11-10 Dipeptides for prevention of muscle breakdown and microbial infection Expired - Fee Related US7855181B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/704,936 US7855181B2 (en) 1999-08-13 2003-11-10 Dipeptides for prevention of muscle breakdown and microbial infection
US12/253,590 US8133868B2 (en) 1999-08-13 2008-10-17 Dipeptides for prevention of muscle breakdown and microbial infection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14936999P 1999-08-13 1999-08-13
US63649100A 2000-08-11 2000-08-11
US10/704,936 US7855181B2 (en) 1999-08-13 2003-11-10 Dipeptides for prevention of muscle breakdown and microbial infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US63649100A Continuation 1999-08-13 2000-08-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/253,590 Continuation US8133868B2 (en) 1999-08-13 2008-10-17 Dipeptides for prevention of muscle breakdown and microbial infection

Publications (2)

Publication Number Publication Date
US20040097426A1 US20040097426A1 (en) 2004-05-20
US7855181B2 true US7855181B2 (en) 2010-12-21

Family

ID=46300305

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/704,936 Expired - Fee Related US7855181B2 (en) 1999-08-13 2003-11-10 Dipeptides for prevention of muscle breakdown and microbial infection
US12/253,590 Expired - Fee Related US8133868B2 (en) 1999-08-13 2008-10-17 Dipeptides for prevention of muscle breakdown and microbial infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/253,590 Expired - Fee Related US8133868B2 (en) 1999-08-13 2008-10-17 Dipeptides for prevention of muscle breakdown and microbial infection

Country Status (1)

Country Link
US (2) US7855181B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082283A1 (en) * 1999-08-13 2009-03-26 Josef Neu Dipeptides for Prevention of Muscle Breakdown and Microbial Infection
US20140286923A1 (en) * 2011-11-03 2014-09-25 University Of Florida Reseach Foundation, Inc. Nutritional supplement for weight management

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340592A (en) 1980-03-14 1982-07-20 Adibi Siamak A Nutrient compositions and method of administering the same
EP0087751B1 (en) 1982-02-25 1985-05-29 PFRIMMER KABI GMBH & CO. KG Water-soluble peptides from very poorly soluble amino acids
EP0182356A2 (en) 1984-11-19 1986-05-28 The Montefiore Hospital Association of Western Pennsylvania Nutrient compositions
JPH02119762A (en) 1988-07-01 1990-05-07 Morishita Pharmaceut Co Ltd Nutritive composition blended with oligopeptide of l-glutamine
US5189016A (en) 1990-05-18 1993-02-23 Clintec Nutrition Co. Nutrient compositions containing peptides and method for administering the same
EP0087750B2 (en) 1982-02-25 1994-04-27 Kabi Pharmacia GmbH Amino acid preparations containing glutaminic residues
US5561111A (en) 1994-12-23 1996-10-01 The University Of Virginia Patent Foundation Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy
JPH08295633A (en) 1995-03-01 1996-11-12 Otsuka Pharmaceut Factory Inc Complication-preventing agent for patient in high protein catabolismic state
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
WO1998009985A2 (en) 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
US6051270A (en) 1997-11-05 2000-04-18 Galagen, Inc. Liquid amino acid nutritional composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627735A5 (en) * 1976-06-25 1982-01-29 Hoffmann La Roche METHOD FOR PRODUCING DIPEPTIDE DERIVATIVES.
DE19856789A1 (en) 1998-12-09 2000-06-15 Nutricia Nv Thymus growth stimulating baby food
US7855181B2 (en) * 1999-08-13 2010-12-21 University Of Florida Research Foundation, Inc. Dipeptides for prevention of muscle breakdown and microbial infection
WO2005030242A1 (en) * 2003-09-26 2005-04-07 University Of Florida Research Foundation, Inc Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340592A (en) 1980-03-14 1982-07-20 Adibi Siamak A Nutrient compositions and method of administering the same
EP0087751B1 (en) 1982-02-25 1985-05-29 PFRIMMER KABI GMBH & CO. KG Water-soluble peptides from very poorly soluble amino acids
EP0087750B2 (en) 1982-02-25 1994-04-27 Kabi Pharmacia GmbH Amino acid preparations containing glutaminic residues
EP0182356A2 (en) 1984-11-19 1986-05-28 The Montefiore Hospital Association of Western Pennsylvania Nutrient compositions
JPH02119762A (en) 1988-07-01 1990-05-07 Morishita Pharmaceut Co Ltd Nutritive composition blended with oligopeptide of l-glutamine
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5189016A (en) 1990-05-18 1993-02-23 Clintec Nutrition Co. Nutrient compositions containing peptides and method for administering the same
US5561111A (en) 1994-12-23 1996-10-01 The University Of Virginia Patent Foundation Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy
JPH08295633A (en) 1995-03-01 1996-11-12 Otsuka Pharmaceut Factory Inc Complication-preventing agent for patient in high protein catabolismic state
WO1998009985A2 (en) 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6051270A (en) 1997-11-05 2000-04-18 Galagen, Inc. Liquid amino acid nutritional composition

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Abidi, S., et al. "Influence of Molecular Structure on Half-life and Hydrolysis of Dipeptides in Plasma: Importance of Glycine as N-Terminal Amino Acid Residue," Metabolism (1986), vol. 35, No. 9, pp. 830-836.
Cynober, L. "New Nitrogen Substrates in Preoperative Nutrition of the Adult," Ann Fr Anesth Réanim (1995), vol. 14, No. 2, pp. 102-106, only abstract in English.
Le Boucher, et al. "Modulation of immune response with omithine A-ketoglutarate in bum injury: an arginine or glutamine dependency?" Nutrition (1999), vol. 15, No. 10, pp. 773-777.
Matilla, Belén, et al. "Effects of Parental Nutrition Supplemented with Glutamine Dipeptide on Liver Antioxidant and Detoxication Systems in Rats," Nutrition (2000), vol. 16, pp. 125-128.
Mattox et al. "Recent Advances: parental nutrition support," Annals of Pharmacotherapy (1995), vol. 29, No. 2, pp. 174-180.
Miyazawa, K. et al. "Amino-acids and Peptide in 7 Species of Marine Green Algae," Journal of the Faculty of Fisheries and Animal Husbandry Hiroshima (1976), vol. 15, No. 2, pp. 161-169.
Moinard, of al. "Involvement of glutamine, arginine, and polyamines in the action of omithine alpha-ketoglutarate on macrophage functions in stressed rats," Journal of Leukocyte Biology (2000), vol. 67, pp. 834-840.
Neu, Josef, et al. "Glutamine nutrition and metabolism: Where do we go from here?" The FASEB Journal (1996), vol. 10, pp. 829-837.
Robinson, et al. "Amino acid nutrition and immune function in tumour-bearing rats: a comparison of glutamine-, arginine- and omithine 2-oxoglutarate-supplemented diets," Clinical Science (1999), vol. 97, No. 6, pp. 657-669.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082283A1 (en) * 1999-08-13 2009-03-26 Josef Neu Dipeptides for Prevention of Muscle Breakdown and Microbial Infection
US8133868B2 (en) * 1999-08-13 2012-03-13 University Of Florida Research Foundation, Inc. Dipeptides for prevention of muscle breakdown and microbial infection
US20140286923A1 (en) * 2011-11-03 2014-09-25 University Of Florida Reseach Foundation, Inc. Nutritional supplement for weight management
US9327001B2 (en) * 2011-11-03 2016-05-03 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management

Also Published As

Publication number Publication date
US20090082283A1 (en) 2009-03-26
US8133868B2 (en) 2012-03-13
US20040097426A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
EP0347890B1 (en) Amino acid nutrient compositions
JP5315996B2 (en) Total enteral nutrition composition
AU2009228250B2 (en) Leucine-rich peptide compositions and methods for isolation
NL8101182A (en) FOOD PREPARATIONS AND METHOD OF ADMINISTRATION.
US5189016A (en) Nutrient compositions containing peptides and method for administering the same
JPH0952828A (en) Amino acid composition and its use
EP0540462A1 (en) L-Glutamine or a peptide rich in L-glutamine for the manufacture of an oral formulation for the treatment of a fall in blood L-glutamine levels
JP3068656B2 (en) Novel peptide and angiotensin converting enzyme inhibitory peptide and oral feeding composition containing them
EP1552826A1 (en) Amino acid compositions for improving central functions
US8133868B2 (en) Dipeptides for prevention of muscle breakdown and microbial infection
JPH04327537A (en) Method of insuring sufficient intracellular glutathione in tissue
CA2134380C (en) Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US9138455B2 (en) Activating adiponectin by casein hydrolysate
EP3174548B1 (en) Marine peptides and fish nucleotides, compositions and uses thereof for reducing blood glucose
WO2003017787A1 (en) Dipeptides for prevention of muscle breakdown and microbial infection
JP2006515879A (en) Method for improving nutrient utilization by mammals and compositions for use therein
JPH02128670A (en) Amino acid-containing food composition
JPH07330583A (en) Liquid preparation containing free glutamic acid
JPH09110686A (en) Macrophage nitrogen monoxide-producing sthenic agent
JP2522367B2 (en) Amino acid-containing food composition
MARTIN et al. Intravenous Alimentation With Amino Acids: A Review
WO1995022967A1 (en) Analgesic activity enhancer
JPH07503705A (en) Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof
US20190070139A1 (en) Agent for improving physical fitness
JPH02138952A (en) Nutrient transfusion composition containing dipeptide of l-leucine

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., F

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF FLORIDA;REEL/FRAME:025309/0762

Effective date: 20101028

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20181221